Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06710327 · ClinicalTrials.gov registry record · Phase 4
Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation
A Phase 4 study, sponsored by Kaiser Permanente.
- Not yet
- Registry status
- Phase 4
- Development phase
- 56
- Enrollment target
NCT06710327 is a Phase 4 study that has not yet begun recruiting, run by Kaiser Permanente. The registered enrollment target is 56 participants.
The verdict
NCT06710327, a Phase 4 study, has not yet begun recruiting, sponsored by Kaiser Permanente.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study aims to find out if tranexamic acid (TXA), a medication, works to decrease blood loss during a specific surgery called Aquablation therapy, which is a treatment for men with Benign Prostatic Hyperplasia (BPH). BPH is a common condition in men over the age of 45 that involves enlargement of the prostate gland and can lead to problems or discomfort with urination. The main goal of this research is to see if TXA can help reduce the amount of blood loss during surgery compared to not using the drug. This is important because losing less blood during surgery can help patients recover faster and more safely. Researchers will monitor the safety of TXA and its effects on other outcomes, like the length of hospital stay and any possible changes in blood tests that check how well blood clots. Participants in this study will: * Be males diagnosed with BPH who are already scheduled to undergo Aquablation therapy. * Be randomly assigned to either receive TXA or a placebo (a look-alike substance that contains no drug) right before their surgery. * Not know which treatment they are receiving to make sure the results are unbiased. Researchers hope to engage participants who meet the health criteria of the study. They will be carefully monitored before, during, and after the surgery for any health changes, and their blood loss during surgery will be measured. This study does not require any additional time commitment outside of the standard surgical process, and all treatments will be provided at no additional cost to the participants. The researchers will ensure that all participants understand the procedure and support their safety throughout the research.
Interventions
- DRUG Placebo
- DRUG Tranexamic Acid (IV)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-01 |
| Est. Completion | 2025-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06710327
The ClinicalTrials.gov registry entry for NCT06710327 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06710327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06710327 about?
NCT06710327 is a clinical study titled "Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation". This study aims to find out if tranexamic acid (TXA), a medication, works to decrease blood loss during a specific surgery called Aquablation therapy, which is a treatment for men with Benign Prostatic Hyperplasia (BPH). BPH is a common condition in men over the age of 45 that involves enlargement o...
What is the current status of trial NCT06710327?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 56 participants. The study started on 2025-01. Estimated completion is 2025-08.
What interventions are being tested in trial NCT06710327?
The interventions under investigation include: Placebo (DRUG), Tranexamic Acid (IV) (DRUG).
Who is sponsoring clinical trial NCT06710327?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.